Literature DB >> 36155866

Expression of GLUT4 and FAP in urothelial bladder carcinoma: correlation with angiogenesis and clinicopathological characteristics.

Marwa A Abd El-Azeem1, Mona A Ali2, Safinaz H El-Shorbagy2.   

Abstract

BACKGROUND: Urothelial carcinoma (UC) is the most common type of bladder cancer. Glucose transporter 4 (GLUT4) is one of glucose transporter proteins' family which facilitates glucose transport inside the cells. It was found to be overexpressed in several malignant tumors. Cancer-associated fibroblasts (CAFs) are heterogeneous stromal cells located adjacent to cancer cells and are considered one of the most important tumor stromal cells. They have been associated with enhancing tumor growth and invasion. GLUT4 expression in malignant epithelial cells and fibroblast activation protein (FAP) expression in CAFs of UC in relation to angiogenesis and clinicopathological characteristics are studied in this work.
MATERIALS AND METHODS: The study was carried out on 72 paraffin blocks of UC (27 radical cystectomies and 45 transurethral resections). Immunohistochemical staining was performed with GLUT4, FAP, and CD34 antibodies. Expression of GLUT4 and FAP was classified according to the staining intensities and percentages into low and high groups. CD34-stained microvessels' mean count in five microscopic fields (×200) was taken as the microvessel density (MVD).
RESULTS: GLUT4 overexpression was detected in 32 UC. It was significantly associated with high-grade tumors, advanced primary tumor (pT) stage, lymphovascular invasion (LVI), and regional lymph node invasion. High FAP expression was appreciated in 27 UC and was significantly linked to LVI and advanced TNM staging. Intratumor MVD significantly increased in UC with muscle invasion, LVI, and regional lymph node and/or distant metastasis. A significant positive correlation between GLUT4, FAP expression, and MVD was found.
CONCLUSION: GLUT4 and FAP expression was significantly associated with increased intratumor MVD and adverse clinicopathological factors.
© 2022. The Author(s).

Entities:  

Keywords:  Angiogenesis; Clinicopathological characteristics; FAP; GLUT4; Immunohistochemistry; Urothelial carcinoma

Mesh:

Substances:

Year:  2022        PMID: 36155866     DOI: 10.1186/s43046-022-00145-0

Source DB:  PubMed          Journal:  J Egypt Natl Canc Inst        ISSN: 1110-0362


  23 in total

1.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

2.  Matrix crosslinking forces tumor progression by enhancing integrin signaling.

Authors:  Kandice R Levental; Hongmei Yu; Laura Kass; Johnathon N Lakins; Mikala Egeblad; Janine T Erler; Sheri F T Fong; Katalin Csiszar; Amato Giaccia; Wolfgang Weninger; Mitsuo Yamauchi; David L Gasser; Valerie M Weaver
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

Review 3.  Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins.

Authors:  I Stuart Wood; Paul Trayhurn
Journal:  Br J Nutr       Date:  2003-01       Impact factor: 3.718

4.  High Glucose Promotes Epithelial-Mesenchymal Transition of Uterus Endometrial Cancer Cells by Increasing ER/GLUT4-Mediated VEGF Secretion.

Authors:  Chun-Jie Gu; Feng Xie; Bing Zhang; Hui-Li Yang; Jiao Cheng; Yin-Yan He; Xiao-Yong Zhu; Da-Jin Li; Ming-Qing Li
Journal:  Cell Physiol Biochem       Date:  2018-10-11

5.  Effects of metformin on the expression of GLUT4 in endometrium of obese women with polycystic ovary syndrome.

Authors:  Jun Zhai; Chun-xi Liu; Zuo-rong Tian; Qiu-hui Jiang; Ying-pu Sun
Journal:  Biol Reprod       Date:  2012-08-02       Impact factor: 4.285

Review 6.  Aerobic glycolysis: beyond proliferation.

Authors:  William Jones; Katiuscia Bianchi
Journal:  Front Immunol       Date:  2015-05-15       Impact factor: 7.561

7.  Glucose transporter 4 promotes head and neck squamous cell carcinoma metastasis through the TRIM24-DDX58 axis.

Authors:  Yu-Chan Chang; Li-Hsing Chi; Wei-Ming Chang; Chia-Yi Su; Yuang-Feng Lin; Chi-Long Chen; Ming-Huang Chen; Peter Mu-Hsin Chang; Alex T H Wu; Michael Hsiao
Journal:  J Hematol Oncol       Date:  2017-01-07       Impact factor: 17.388

8.  Fibroblasts in urothelial bladder cancer define stroma phenotypes that are associated with clinical outcome.

Authors:  Artur Mezheyeuski; Ulrika Segersten; Lina Wik Leiss; Per-Uno Malmström; Jiri Hatina; Arne Östman; Carina Strell
Journal:  Sci Rep       Date:  2020-01-14       Impact factor: 4.379

9.  Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients.

Authors:  Wilma E Mesker; Gerrit-Jan Liefers; Jan M C Junggeburt; Gabi W van Pelt; Paola Alberici; Peter J K Kuppen; Noel F Miranda; Karin A M van Leeuwen; Hans Morreau; Karoly Szuhai; Rob A E M Tollenaar; Hans J Tanke
Journal:  Cell Oncol       Date:  2009       Impact factor: 6.730

Review 10.  miRNAs: A Promising Target in the Chemoresistance of Bladder Cancer.

Authors:  Zhonglin Cai; Fa Zhang; Weijie Chen; Jianzhong Zhang; Hongjun Li
Journal:  Onco Targets Ther       Date:  2019-12-31       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.